跳至主要内容
临床试验/JPRN-jRCTs071220071
JPRN-jRCTs071220071招募中2 期

Treatment protocol for adult acute lymphoblastic leukemia (-ALL/MRD2023-) - JSCT ALL/MRD2023

Koichi Akashi0 个研究点目标入组 210 人开始时间: 2022年11月24日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
210

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 16age old 至 <= 65age old(—)
性别
All

入选标准

  • 1.Cases diagnosed with acute lymphocytic leukemia in the WHO classification (2017) with more than 26% blasts in the bone marrow, or mixed phenotype acute leukemia (MPAL) in the WHO classification (2017). Patients with more than 26% blasts in the bone marrow and undergoing ALL-directed chemotherapy. The WHO classification (2017 edition) is used as the diagnostic criteria for MPAL in this study.
  • 3.First-time treatment patients who have not received chemotherapy or radiotherapy.
  • 3.Patients aged between 16 and 65 years old.
  • 4.Performance status (ECOG): 0 to 2 cases.
  • 5.Cases without severe organ damage. T. Bil=<2.0mg/dL, Cr=<2.0mg/dL
  • 6.Patients who have given written consent from the patient after explaining the content of this research. However, in the case of minors, written consent has been obtained from the legal representative and the individual.

排除标准

  • 1. Blast cell surface immunoglobulin-positive Burkitt leukemia.
  • 2.Patients with active double cancer.
  • 3.Patients with difficult-to-control infections.
  • 4. Cases with severe mental disorders.
  • 5. Pregnant cases.
  • 6.Other cases judged inappropriate by the attending physician.

研究者

发起方
Koichi Akashi

相似试验